North China Pharmaceutical Co (SHSE:600812) ROIC %: 2.03% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600812 North China Pharmaceutical Co Ltd SHSE:600812
45 GF Score
Price ¥4.82
GF Value ¥4.86
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is North China Pharmaceutical Co ROIC %?

North China Pharmaceutical Co SHSE:600812 +0.21% 45 ROIC % is 2.03% as of Mar. 2026. GuruFocus rates SHSE:600812 with a GF Score™ of 45/100 and a GF Value™ of ¥4.86 (Fairly Valued). The stock has 6 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. North China Pharmaceutical Co's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2026 was 2.03%.

As of today (2026-07-23), North China Pharmaceutical Co's WACC % is 5.53%. North China Pharmaceutical Co's ROIC % is 2.00% (calculated using TTM income statement data). North China Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


North China Pharmaceutical Co  (SHSE:600812) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, North China Pharmaceutical Co's WACC % is 5.53%. North China Pharmaceutical Co's ROIC % is 2.00% (calculated using TTM income statement data). North China Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


North China Pharmaceutical Co ROIC % Related Terms


North China Pharmaceutical Co ROIC % Historical Data

* Premium members only.

The historical data trend for North China Pharmaceutical Co's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

North China Pharmaceutical Co ROIC % Chart

North China Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 3.56 0.91 2.45 2.18

North China Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.74 2.76 1.41 1.77 2.03

SHSE:600812 vs ZTS, UTHR: ROIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, North China Pharmaceutical Co's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


North China Pharmaceutical Co ROIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, North China Pharmaceutical Co's ROIC % distribution charts can be found below:

* The bar in red indicates where North China Pharmaceutical Co's ROIC % falls into.


SHSE:600812
45GF Score
North China Pharmaceutical Co Ltd SHSE:600812
ROIC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

North China Pharmaceutical Co ROIC % Calculation

North China Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROIC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=665.558 * ( 1 - 27.97% )/( (21258.556 + 22654.283)/ 2 )
=479.4014274/21956.4195
=2.18 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21471.458 - 2915.152 - ( 1660.279 - max(0, 10961.53 - 8259.28+1660.279))
=21258.556

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21391.903 - 3005.588 - ( 1541.414 - max(0, 12399.264 - 8131.296+1541.414))
=22654.283

North China Pharmaceutical Co's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2026 is calculated as:

ROIC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=602.824 * ( 1 - 25.5% )/( (22654.283 + 21632.572)/ 2 )
=449.10388/22143.4275
=2.03 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21391.903 - 3005.588 - ( 1541.414 - max(0, 12399.264 - 8131.296+1541.414))
=22654.283

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=21452.011 - 2990.756 - ( 1384.872 - max(0, 11436.667 - 8265.35+1384.872))
=21632.572

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of 2.03% mean?
North China Pharmaceutical Co (SHSE:600812) has a ROIC % of 2.03% as of Mar. 2026. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on North China Pharmaceutical Co and its competitors.
Is North China Pharmaceutical Co's ROIC % too high?
North China Pharmaceutical Co's current ROIC % is 2.03%. The Drug Manufacturers industry median ROIC % is 4.44. North China Pharmaceutical Co's value of 2.03% is 54.3% below this industry median. Overall, North China Pharmaceutical Co has a GF Score™ of 45/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does North China Pharmaceutical Co's ROIC % compare to ZTS and UTHR?
North China Pharmaceutical Co's ROIC % of 2.03% can be compared against companies in the Drug Manufacturers industry. The industry median ROIC % is 4.44. North China Pharmaceutical Co's value of 2.03% is 54.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Drug Manufacturers company?
The median ROIC % among Drug Manufacturers companies is 4.44, based on 988 companies in the industry. Companies in the top quartile (top 25%) have a ROIC % significantly above this median, while those in the bottom quartile fall well below. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. North China Pharmaceutical Co's current ROIC % of 2.03% is 54.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on North China Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. North China Pharmaceutical Co's current ROIC % is 2.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is North China Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, North China Pharmaceutical Co (SHSE:600812) is currently considered Fairly Valued. The stock's GF Value™ is ¥4.86, compared to a current price of ¥4.82 — trading 0.8% below its estimated fair value. The current ROIC % is 2.03% and 54.3% below the Drug Manufacturers industry median of 4.44. North China Pharmaceutical Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For North China Pharmaceutical Co (SHSE:600812), the current ROIC % is 2.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is North China Pharmaceutical Co (SHSE:600812) Overvalued in 2026?

Based on GuruFocus' analysis, North China Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥4.82 is trading 0.8% below its estimated GF Value™ of ¥4.86. GuruFocus considers North China Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600812:

  • ROIC %: 2.03%
  • GF Value™: ¥4.86 vs. price of ¥4.82 (0.8% below fair value)
  • GF Score™: 45/100 with 6 warning signs
  • Industry Position: 54.3% below the Drug Manufacturers median

No single metric tells the full story. See the SHSE:600812 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


North China Pharmaceutical Co Business Description

Address No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
45GF Score

Get the complete analysis for SHSE:600812

ROIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥4.82
Price
¥4.86
GF Value